

SUPPLEMENTARY MATERIAL

Supplementary table 1: Medicines and Healthcare products Regulatory Agency indications of anti-programmed cell death protein 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) monoclonal antibodies obtained 25th March 2023 (* represents monotherapy indications and ** represents indications as part of combination therapy).

Molecular markers: epidermal growth factor receptor gene (*EGFR*), anaplastic lymphoma kinase gene (*ALK*), c-ros oncogene 1 gene (*ROS1*), deficient mismatch repair (dMMR), microsatellite instability high (MSI-H), combined positive score (CPS), tumour proportion score (TPS).

Cancers: non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC).

Target	Drug	Cancer						
		Breast	Colorectal	Head and neck	Lung	Melanoma	Ovarian	Prostate
PD-1	Cemiplimab (13)	-	-	-	• Metastatic or locally advanced PD-L1 ≥ 50% TPS NSCLC (<i>EGFR</i> , <i>ALK</i> , <i>ROS1</i> wildtype)*	-	-	-
	Dostarlimab (14)	-	-	-	-	-	-	
	Nivolumab (15)	-	• dMMR/MSI-H colorectal cancer following chemotherapy**	• Metastatic or recurrent HNSCC following prior treatment*	• Metastatic NSCLC (<i>EGFR</i> , <i>ALK</i> wild type)** • Metastatic or locally advanced NSCLC following chemotherapy* • Resectable NSCLC**	• Metastatic or unresectable melanoma*.** • Metastatic or lymph node involved melanoma patients following complete resection*	-	-

	Pembrolizumab (16)	<ul style="list-style-type: none"> • Locally advanced or early-stage TNBC with high risk of recurrence*** • Metastatic or locally recurrent unresectable PD-L1 CPS \geq 10 TNBC** 	<ul style="list-style-type: none"> • Treatment-naïve metastatic dMMR/MSI-H colorectal cancer* • Metastatic or unresectable dMMR/MSI-H colorectal cancer following prior treatment* 	<ul style="list-style-type: none"> • Treatment-naïve metastatic or unresectable recurrent PD-L1 CPS \geq 1 HNSCC*** • Metastatic or recurrent PD-L1 TPS \geq 50% HNSCC following prior chemotherapy* 	<ul style="list-style-type: none"> • Metastatic NSCLC with PD-L1 \geq 50% TPS (<i>EGFR</i>, <i>ALK</i> wild-type)*** • Metastatic or locally advanced PD-L1 \geq 1% TPS NSCLC following chemotherapy and targeted therapy (if applicable)* 	<ul style="list-style-type: none"> • Metastatic or unresectable melanoma* • Completely resected stage IIB, IIC, III melanoma* 		
PD-L1	Atezolizumab (17)	<ul style="list-style-type: none"> • Metastatic or locally advanced PD-L1 \geq 1% TPS TNBC** 			<ul style="list-style-type: none"> • Completely resected stage II-III A NSCLC with PD-L1 \geq 50% and no progression on prior chemotherapy* • Metastatic nonsquamous NSCLC** • Metastatic NSCLC PD-L1 \geq 50% TPS (<i>EGFR</i>, <i>ALK</i> wildtype)* • Metastatic or locally advanced NSCLC following chemotherapy and targeted therapy (if applicable)* • Treatment-naïve extensive stage SCLC** 			
	Avelumab (18)							

	Durvalumab (19)				<ul style="list-style-type: none">• Locally advanced unresectable PD-L1 \geq 1% TPS NSCLC without progression on chemoradiation*• Treatment-naïve extensive-stage SCLC**			
--	-----------------	--	--	--	--	--	--	--